Close Menu

NEW YORK – Takeda Pharmaceuticals said on Monday that its supplemental new drug application to expand the use of brigatinib (Alunbrig) as a first-line treatment for ALK-positive non-small cell lung cancer patients was accepted by the US Food and Drug Administration and granted priority review.

Approximately 3 to 5 percent of NSCLC patients have a rearrangement in the anaplastic lymphoma kinase (ALK). In that subset, the chromosomal alteration was found to be a key driver of disease.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.